CG009301

· Cullgen (Shanghai), Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CG009301, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies [Phase 1]

See pricing